SG11201404477YA - HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS - Google Patents

HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS

Info

Publication number
SG11201404477YA
SG11201404477YA SG11201404477YA SG11201404477YA SG11201404477YA SG 11201404477Y A SG11201404477Y A SG 11201404477YA SG 11201404477Y A SG11201404477Y A SG 11201404477YA SG 11201404477Y A SG11201404477Y A SG 11201404477YA SG 11201404477Y A SG11201404477Y A SG 11201404477YA
Authority
SG
Singapore
Prior art keywords
domains
heavy chains
chains containing
express heavy
humanized rodents
Prior art date
Application number
SG11201404477YA
Inventor
Lynn Macdonald
Cagan Gurer
Karolina A Meagher
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11201404477YA publication Critical patent/SG11201404477YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
SG11201404477YA 2012-02-01 2013-02-01 HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS SG11201404477YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US201261677538P 2012-07-31 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Publications (1)

Publication Number Publication Date
SG11201404477YA true SG11201404477YA (en) 2014-08-28

Family

ID=47714588

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201913428QA SG10201913428QA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
SG10201606256TA SG10201606256TA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
SG11201404477YA SG11201404477YA (en) 2012-02-01 2013-02-01 HUMANIZED RODENTS THAT EXPRESS HEAVY CHAINS CONTAINING V<sb>L</sb> DOMAINS

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201913428QA SG10201913428QA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains
SG10201606256TA SG10201606256TA (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Country Status (26)

Country Link
US (3) US20130212719A1 (en)
EP (3) EP3597038B1 (en)
JP (6) JP2015505477A (en)
KR (2) KR20190006029A (en)
CN (2) CN106117364B (en)
AU (3) AU2013204758B2 (en)
BR (1) BR112014018843B1 (en)
CA (1) CA2863175A1 (en)
CY (2) CY1122419T1 (en)
DK (2) DK2809150T3 (en)
ES (2) ES2870703T3 (en)
HK (1) HK1202771A1 (en)
HR (2) HRP20192218T1 (en)
HU (2) HUE055610T2 (en)
IL (3) IL233827A0 (en)
LT (2) LT3597038T (en)
ME (1) ME03611B (en)
MX (2) MX2020003491A (en)
NZ (3) NZ734504A (en)
PL (2) PL2809150T3 (en)
PT (2) PT2809150T (en)
RS (2) RS62023B1 (en)
RU (2) RU2770016C2 (en)
SG (3) SG10201913428QA (en)
SI (2) SI3597038T1 (en)
WO (1) WO2013116609A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2288623T3 (en) * 2008-05-23 2014-01-27 Ablexis Llc PROCEDURE FOR CREATING SINGLE-VL DOMAIN ANTIBODIES OF TRANSGENE ANIMALS
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
DK3028564T5 (en) 2009-07-08 2024-04-29 Kymab Ltd ANIMAL MODELS AND THERAPEUTIC MOLECULES
JP6146913B2 (en) * 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Mice producing a binding protein containing a VL domain
EP3865581A1 (en) 2011-08-05 2021-08-18 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
DK2757875T3 (en) 2011-09-19 2018-01-08 Kymab Ltd MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
KR102081657B1 (en) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
RS62023B1 (en) * 2012-02-01 2021-07-30 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
SG11201407789RA (en) 2012-06-12 2014-12-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2014218915B2 (en) 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
EP3794941A1 (en) 2013-10-01 2021-03-24 Kymab Limited Animal models and therapeutic molecules
EP3119194B1 (en) 2014-03-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2941514A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
EP3277823B1 (en) * 2015-04-03 2023-09-13 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
RU2021106817A (en) 2016-05-20 2021-04-06 Регенерон Фармасьютикалс, Инк. METHODS FOR OVERCOMING IMMUNOLOGICAL TOLERANCE WITH THE USE OF MANY GUIDING RNA
CN110719732B (en) * 2017-03-30 2022-11-18 犹他州立大学 Transgenic silkworms expressing spider silk
HUE060608T2 (en) * 2017-12-05 2023-03-28 Regeneron Pharma Mice having an engineered immunoglobulin lambda light chain and uses thereof
CN112040769B (en) * 2018-03-24 2023-05-16 瑞泽恩制药公司 Genetically modified non-human animals, methods of manufacture and use for producing therapeutic antibodies against peptide-MHC complexes
US20190380316A1 (en) * 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
KR20230147048A (en) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 Mice expressing humanized Fc alpha receptors
CN114645042A (en) * 2020-12-18 2022-06-21 中国食品药品检定研究院 Method for constructing transgenic mouse with recombinant macrophage for expressing luciferase and red fluorescent protein
CN114196626A (en) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 Umbilical cord mesenchymal stem cells and isolated culture and amplification method thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
EA013564B1 (en) * 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Humanized immunoglobulin and pharmaceutical composition comprising thereof
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (en) * 2000-11-17 2007-08-15 罗切斯特大学 In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
WO2005007696A2 (en) * 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
PT1802193E (en) 2004-10-19 2014-06-23 Regeneron Pharma Method for generating a mouse homozygous for a genetic modification
US20060117398A1 (en) * 2004-10-22 2006-06-01 Roland Buelow Suppression of endogenous immunoglobulin expression
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
JP5087625B2 (en) * 2006-09-01 2012-12-05 セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
US8426565B2 (en) * 2007-08-30 2013-04-23 Walter And Eliza Hall Institute Of Medical Research Dendritic cell marker and uses thereof
ES2566957T3 (en) * 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Constant region of modified antibody
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
DK2288623T3 (en) * 2008-05-23 2014-01-27 Ablexis Llc PROCEDURE FOR CREATING SINGLE-VL DOMAIN ANTIBODIES OF TRANSGENE ANIMALS
SI3456190T1 (en) * 2008-06-27 2022-06-30 Merus N.V. Antibody producing transgenic murine animal
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
WO2010091182A2 (en) * 2009-02-04 2010-08-12 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
US20120204278A1 (en) * 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
DK3028564T5 (en) * 2009-07-08 2024-04-29 Kymab Ltd ANIMAL MODELS AND THERAPEUTIC MOLECULES
RU2425880C2 (en) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Method of producing transgene mice
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
JP6146913B2 (en) * 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Mice producing a binding protein containing a VL domain
ES2748832T5 (en) * 2011-02-25 2023-06-08 Regeneron Pharma ADAM6 Mice
EP3865581A1 (en) * 2011-08-05 2021-08-18 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
KR102081657B1 (en) * 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 Humanized light chain mice
RS62023B1 (en) * 2012-02-01 2021-07-30 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
SG11201407789RA (en) * 2012-06-12 2014-12-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
HRP20220888T1 (en) * 2016-11-04 2022-10-28 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus

Also Published As

Publication number Publication date
BR112014018843B1 (en) 2024-02-20
US20130212719A1 (en) 2013-08-15
RU2014133653A (en) 2016-03-20
EP3912465A1 (en) 2021-11-24
HRP20210987T1 (en) 2021-09-17
NZ734504A (en) 2022-10-28
US20170094955A1 (en) 2017-04-06
SG10201913428QA (en) 2020-03-30
RU2018122695A3 (en) 2021-10-06
ES2870703T3 (en) 2021-10-27
BR112014018843A8 (en) 2019-01-29
NZ719228A (en) 2022-08-26
LT3597038T (en) 2021-05-25
BR112014018843A2 (en) 2017-07-04
SG10201606256TA (en) 2016-09-29
PT3597038T (en) 2021-05-10
IL268675B (en) 2020-11-30
AU2015246154A1 (en) 2015-11-12
AU2013204758B2 (en) 2015-07-23
CN104202971A (en) 2014-12-10
LT2809150T (en) 2019-10-25
JP2023014242A (en) 2023-01-26
RS59699B1 (en) 2020-01-31
JP6698718B2 (en) 2020-05-27
PL2809150T3 (en) 2020-04-30
DK3597038T3 (en) 2021-06-28
ME03611B (en) 2020-07-20
KR20140123983A (en) 2014-10-23
AU2017251848B2 (en) 2020-02-20
MX2019002517A (en) 2019-06-17
CN106117364A (en) 2016-11-16
EP3597038A1 (en) 2020-01-22
CA2863175A1 (en) 2013-08-08
CY1124361T1 (en) 2022-07-22
PT2809150T (en) 2019-12-09
HRP20192218T1 (en) 2020-03-06
US20210368751A1 (en) 2021-12-02
DK2809150T3 (en) 2019-12-09
IL261280A (en) 2018-10-31
RU2770016C2 (en) 2022-04-14
NZ627977A (en) 2016-06-24
SI3597038T1 (en) 2021-07-30
EP2809150B1 (en) 2019-09-18
AU2013204758A1 (en) 2013-08-15
IL268675A (en) 2019-10-31
MX2020003491A (en) 2022-10-25
HUE046744T2 (en) 2020-03-30
RS62023B1 (en) 2021-07-30
CN104202971B (en) 2016-07-06
WO2013116609A1 (en) 2013-08-08
JP2015505477A (en) 2015-02-23
RU2018122695A (en) 2019-03-06
CY1122419T1 (en) 2021-01-27
SI2809150T1 (en) 2019-11-29
JP7187615B2 (en) 2022-12-12
JP2021137030A (en) 2021-09-16
JP6942757B2 (en) 2021-09-29
HK1202771A1 (en) 2015-10-09
ES2753774T3 (en) 2020-04-14
AU2015246154B2 (en) 2017-11-23
EP2809150A1 (en) 2014-12-10
JP2018075041A (en) 2018-05-17
IL261280B (en) 2019-08-29
CN106117364B (en) 2021-08-31
IL233827A0 (en) 2014-09-30
PL3597038T3 (en) 2021-11-08
KR20190006029A (en) 2019-01-16
RU2664185C2 (en) 2018-08-15
JP2023168590A (en) 2023-11-24
EP3597038B1 (en) 2021-04-21
HUE055610T2 (en) 2021-12-28
JP2019170395A (en) 2019-10-10
AU2017251848A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
IL268675B (en) Humanized rodents that express heavy chains containing vl domains
IL268674A (en) Humanized il-7 rodents
HK1215267A1 (en) Chimeric antigen receptors
HK1213922A1 (en) M971 chimeric antigen receptors m971
AP2014008002A0 (en) Anti-baff-anti-IL-17 bispecific antibodies
PL3058134T3 (en) Extracellular polymers from granular sludge as sizing agents
DK2798120T3 (en) Coverbraided rope for pelagic trawls
EP2893041A4 (en) Chimeric anti-dsdna/chromatin antibody
GB201210663D0 (en) Faeces container